NCT07169630View on ClinicalTrials.gov

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

April 11, 2029

Study Completion Date

April 11, 2030

Conditions
Alzheimer s DiseaseMild Cognitive ImpairmentHealthy
Interventions
DRUG

18F-PF974

Injected IV followed by PET scanning

DRUG

18F-florbetaben

Injected IV followed by PET scanning

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH

NCT07169630 - PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) | Biotech Hunter | Biotech Hunter